Deleted Tweets From Scott Gottlieb, R-D.C.

RT @FishburnSimone: If FDA gets the $400 million boost proposed in the budget, this is how it wiill spend it. By @steveusdin1 in today'… https://t.co/PR5GiP1MZ1

RT @DrMarcSiegel: Detect concussions with a blood test? https://t.co/hKnsBDFhfV @cvpayne @Varneyco @FoxBusiness @foxnewshealth… https://t.co/RL0AAuOBIB

Consider using less costly #generics as safe and effective alternatives to your more costly brand-name medicines. Get your questions answered here: https://t.co/mNXhzawnlc https://t.co/Db2uY3cFgK

#FDA’s proposal to invest in a conversion by industry to continuous manufacturing - contained in the FY19 budget - can help reduce drug shortages; streamline #flu vaccine production; improve quality; and re-domesticate more drug and biologics manufacturin

As part of FY19 request in @POTUS budget to support medical product innovation, access, and U.S. technology industry; #FDA proposes to invest in build-out of 503B pharmacy outsourcing sector and make it more efficient for compounders to meet GMP standards

We’ve updated our standards for accepting clinical data from medical device studies conducted outside U.S. for applications submitted to the #FDA to increase efficiency, protect patients, and improve data quality and integrity link: https://t.co/6EaK7skxs

Today’s #FDA & @CDCgov warning on a multistate Salmonella outbreak adds to our safety concerns about kratom. There’s no safe kratom product. In addition to this outbreak, kratom is an opioid; expected to have similar risks of addiction, abuse, and dea

The docket is now open for public input on #FDA’s efforts to re-evaluate and modernize #FDA’s approach to development and regulation of nicotine replacement therapy products to help smokers quit cigarettes: https://t.co/tukPliNYe2 https://t.co/DUV27zFyjX

Advancing medicinal nicotine replacement therapies that help smokers quit is a key piece of our comprehensive approach to reduce smoking-related disease and death. #FDA’s Nicotine Steering Committee’s docket for public comment on these issues opened today

RT @US_FDA: There are no FDA-approved uses for kratom & the agency has received concerning reports about the safety of kratom,… https://t.co/ReVp972ddd

RT @ASCOPost: "We’re commited to enhancing transparency about the work we do at the FDA, especially when it has the potential to… https://t.co/uGGw2c6ic5

RT @FDAfood: #Physicians you're a very important component to combating the spread of #foodborne illness – Suspect, Identify, Tr… https://t.co/zBjlkAzZ22

RT @FDAcdrhIndustry: FDA issues final rule on “Human Subject Protection; Acceptance of Data from Clinical Investigations for Medical Dev… https://t.co/AgjMdoqidM

RT @FDAOncology: Webcast happening now: https://t.co/CjmxwEg0eL https://t.co/2DYEoK0RNh QT @DrAJWalker: Great discussion / debate at #RxRTCombos18 regarding the importance of preclinical data. And then Paul Harari broug… https://t.co/X4VJ6dShdV)

RT @dgingery: Thursday morning reading: Gottlieb's Priority For Proposed Opioid Money Is Mail Facilities https://t.co/9ftTFN9JGK

#FDA and AMA launched a new video to empower consumers to help prevent foodborne illness when storing, preparing and serving food:https://t.co/We2DCgWyAK https://t.co/CkjLZvCq5Y

“These new provisions and FDA’s draft guidance will hopefully provide greater clarity to sponsors about how to demonstrate that clinical data collected from clinical investigations conducted OUS are adequate under FDA’s standards.” https://t.co/qT6ALBEc4B QT @fdalawblog: FDA Publishes Final Rule and Draft Guidance on Acceptance of Clinical Data to Support Medical Device Applications a… https://t.co/LXTjcBCk6P)

The @US_FDA is grateful for the public health leadership of @Surgeon_General Adams in his efforts to promote smoking cessation and alternatives to combustible cigarettes to address nicotine addiction https://t.co/cb4bAZ3chr

RT @FDATobacco: FDA Commissioner @SGottliebFDA and CTP Director Mitch Zeller will discuss FDA’s comprehensive plan on tobacco and n… https://t.co/widrMuXfmP

RT @steveusdin1: FDA planning pilot program for innovative trial designs https://t.co/38wxWJ1QuH

RT @FishburnSimone: If FDA gets the $400 million boost proposed in the budget, this is how it wiill spend it. By @steveusdin1 in today'… https://t.co/PR5GiP1MZ1

RT @DrMarcSiegel: Detect concussions with a blood test? https://t.co/hKnsBDFhfV @cvpayne @Varneyco @FoxBusiness @foxnewshealth… https://t.co/RL0AAuOBIB

Consider using less costly #generics as safe and effective alternatives to your more costly brand-name medicines. Get your questions answered here: https://t.co/mNXhzawnlc https://t.co/Db2uY3cFgK

#FDA’s proposal to invest in a conversion by industry to continuous manufacturing - contained in the FY19 budget - can help reduce drug shortages; streamline #flu vaccine production; improve quality; and re-domesticate more drug and biologics manufacturin

As part of FY19 request in @POTUS budget to support medical product innovation, access, and U.S. technology industry; #FDA proposes to invest in build-out of 503B pharmacy outsourcing sector and make it more efficient for compounders to meet GMP standards

We’ve updated our standards for accepting clinical data from medical device studies conducted outside U.S. for applications submitted to the #FDA to increase efficiency, protect patients, and improve data quality and integrity link: https://t.co/6EaK7skxs

Today’s #FDA & @CDCgov warning on a multistate Salmonella outbreak adds to our safety concerns about kratom. There’s no safe kratom product. In addition to this outbreak, kratom is an opioid; expected to have similar risks of addiction, abuse, and dea

The docket is now open for public input on #FDA’s efforts to re-evaluate and modernize #FDA’s approach to development and regulation of nicotine replacement therapy products to help smokers quit cigarettes: https://t.co/tukPliNYe2 https://t.co/DUV27zFyjX

Advancing medicinal nicotine replacement therapies that help smokers quit is a key piece of our comprehensive approach to reduce smoking-related disease and death. #FDA’s Nicotine Steering Committee’s docket for public comment on these issues opened today

RT @US_FDA: There are no FDA-approved uses for kratom & the agency has received concerning reports about the safety of kratom,… https://t.co/ReVp972ddd

RT @ASCOPost: "We’re commited to enhancing transparency about the work we do at the FDA, especially when it has the potential to… https://t.co/uGGw2c6ic5

RT @FDAfood: #Physicians you're a very important component to combating the spread of #foodborne illness – Suspect, Identify, Tr… https://t.co/zBjlkAzZ22

RT @FDAcdrhIndustry: FDA issues final rule on “Human Subject Protection; Acceptance of Data from Clinical Investigations for Medical Dev… https://t.co/AgjMdoqidM

RT @FDAOncology: Webcast happening now: https://t.co/CjmxwEg0eL https://t.co/2DYEoK0RNh QT @DrAJWalker: Great discussion / debate at #RxRTCombos18 regarding the importance of preclinical data. And then Paul Harari broug… https://t.co/X4VJ6dShdV)

RT @dgingery: Thursday morning reading: Gottlieb's Priority For Proposed Opioid Money Is Mail Facilities https://t.co/9ftTFN9JGK

#FDA and AMA launched a new video to empower consumers to help prevent foodborne illness when storing, preparing and serving food:https://t.co/We2DCgWyAK https://t.co/CkjLZvCq5Y

“These new provisions and FDA’s draft guidance will hopefully provide greater clarity to sponsors about how to demonstrate that clinical data collected from clinical investigations conducted OUS are adequate under FDA’s standards.” https://t.co/qT6ALBEc4B QT @fdalawblog: FDA Publishes Final Rule and Draft Guidance on Acceptance of Clinical Data to Support Medical Device Applications a… https://t.co/LXTjcBCk6P)

The @US_FDA is grateful for the public health leadership of @Surgeon_General Adams in his efforts to promote smoking cessation and alternatives to combustible cigarettes to address nicotine addiction https://t.co/cb4bAZ3chr

RT @FDATobacco: FDA Commissioner @SGottliebFDA and CTP Director Mitch Zeller will discuss FDA’s comprehensive plan on tobacco and n… https://t.co/widrMuXfmP

RT @steveusdin1: FDA planning pilot program for innovative trial designs https://t.co/38wxWJ1QuH